Antibody Breaks Leukemia’s Hold, Providing New Therapeutic Approach

In mouse models and patient cells, anti-CD98 antibody disrupts interactions between leukemia cells and surrounding blood vessels, inhibiting cancer’s growth —

Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML. … Read the Full Story from the UC San Diego Newsroom


Dr. Mark Ginsberg

Dr. Mark Ginsberg

Department of Medicine Professor Mark H. Ginsberg, MD, co-directed the study with Tannishtha Reya, PhD, professor of pharmacology.

Dr. Ginsberg is Professor of Medicine in the Division of Rheumatology, Allergy & Immunology at UC San Diego School of Medicine and Moores Cancer Center.

Read the study report

Visit Dr. Ginsberg’s Lab Website